AVAC and TAG Statement on Ethical Conduct of SARS-CoV-2 Vaccine Challenge Studies

Kay Marshall (from AVAC) and Richard Jefferys (from TAG) call on organisations working in health and social care to sign in support of their statement on human challenge studies for COVID-19 vaccine development.

Richard Jefferys writes:
TAG and AVAC are circulating this statement and seeking endorsements from organizations that agree with our position:  https://forms.gle/xatyJBaePmbh25Pw7
As background, challenge trials involve deliberate exposure to a pathogen in order to test vaccines. Typically they involve pathogens for which treatments are available (malaria challenge studies are probably the best known example). A human challenge with SARS-CoV-2 would obviously be very different given the lack of effective treatments and the poorly understood potential consequences of infection, even in young people. Our prior joint statement is available at: https://www.avac.org/press-release/statement-ethical-conduct-challenge-studies
And guiding principles for when challenge studies might be considered are here: https://bit.ly/2CE8slz
Please share the statement with any contacts who might be interested, and feel free to get in touch with any questions.

About AVAC: Founded in 1995, AVAC is a non-profit organization that uses education, policy analysis, advocacy and a network of global collaborations to accelerate the ethical development and global delivery of HIV prevention options as part of a comprehensive response to the pandemic. For more information, visit www.avac.org.

About TAG: Treatment Action Group (TAG) is an independent, activist and community-based research and policy think tank fighting for better treatment, prevention, a vaccine and a cure for HIV, tuberculosis and hepatitis C virus. TAG works to ensure that all people with HIV, TB and HCV receive lifesaving treatment, care and information. We are science-based treatment activists working to expand and accelerate vital research and effective community engagement with research and policy institutions. For more information, visit www.treatmentactiongroup.org.